KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Current Deferred Revenue: 2020-2021

Historic Current Deferred Revenue for Castle Biosciences (CSTL) over the last 2 years, with Sep 2021 value amounting to $3.0 million.

  • Castle Biosciences' Current Deferred Revenue fell 64.08% to $3.0 million in Q3 2021 from the same period last year, while for Sep 2021 it was $3.0 million, marking a year-over-year decrease of 64.08%. This contributed to the annual value of $6.6 million for FY2020, which is N/A change from last year.
  • Latest data reveals that Castle Biosciences reported Current Deferred Revenue of $3.0 million as of Q3 2021, which was down 51.45% from $6.2 million recorded in Q2 2021.
  • In the past 5 years, Castle Biosciences' Current Deferred Revenue ranged from a high of $8.3 million in Q2 2020 and a low of $3.0 million during Q3 2021.
  • Its 2-year average for Current Deferred Revenue is $6.8 million, with a median of $7.4 million in 2020.
  • Data for Castle Biosciences' Current Deferred Revenue shows a maximum YoY slumped of 64.08% (in 2021) over the last 5 years.
  • Over the past 2 years, Castle Biosciences' Current Deferred Revenue (Quarterly) stood at $6.6 million in 2020, then tumbled by 64.08% to $3.0 million in 2021.
  • Its Current Deferred Revenue stands at $3.0 million for Q3 2021, versus $6.2 million for Q2 2021 and $8.2 million for Q1 2021.